Recent studies have identified the involvement of various signaling pathways in tumor innate immunity, notably the cGAS-STING pathway, Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), NOD-like receptors (NLRs), and C-type lectin receptors (CLRs). This evidence concerns the gene LARS1 and neoplasm.